Drugs › Fluoroquinolone antibacterial
Brand name · Moxifloxacin hydrochloride
Vigamox: adverse event reports filed with FDA
801 reports list it as a suspect or interacting product, 2004–2026. Class: Fluoroquinolone antibacterial.
- 801
- reports as suspect product
- 0% of all reports · about 36 a year
- 37
- reports, 12 months to June 2026
- 18 in the 12 months before
- 70.7%
- marked serious by the reporter
- 89.7% across the class
- 1.1%
- record death among outcomes, as reported
- 9 reports · not verified by FDA
801 adverse event reports received by FDA list the brand name Vigamox (moxifloxacin hydrochloride) as a suspect or interacting product, from January 2004 to June 2026. A further 1,573 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 37 reports listed it, up 106% from 18 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 36 reports a year and 0% of the 20,646,523 reports in the database, and 0.9% of the reports for the fluoroquinolone antibacterial class. How many people take it is not in the data, so a count is not a rate of occurrence.
The reactions recorded most often are toxic anterior segment syndrome (11.7%), eye pain (10.5%) and vision blurred (10.4%). A report can list several reactions, so shares add to more than 100%; 261 different terms appear across these reports. Toxic anterior segment syndrome is recorded in 11.7% of these reports, with no counterpart in the median fluoroquinolone antibacterial drug (0%).
70.7% of the reports are marked serious by the reporter (89.7% across the class); 1.1% record death among the outcomes and 8.5% record hospitalisation, as reported. 32.8% of the reports came from consumers, and the largest patient age group is 45 to 64 (15.6%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Vigamox reports recording the termmedian drug in fluoroquinolone antibacterial
- Toxic anterior segment syndrome11.7%94
- Eye paineye pain10.5%84
- Vision blurredblurred vision10.4%83
- Ocular hyperaemiaa red eye9.1%73
- Off label useused for a purpose or in a way not on the label9%72
- Visual acuity reducedreduced sharpness of vision8%64
- Eye irritationeye irritation7.5%60
- Drug ineffectivethe medicine did not work as expected7%56
- Visual impairmentreduced vision6.6%53
- Endophthalmitisinfection inside the eye6.1%49
- Corneal oedema5.9%47
- Eye swellinga swollen eye4.1%33
- Drug hypersensitivityan allergic-type reaction to a medicine3.9%31
- Hypersensitivityan allergic-type reaction3.5%28
- Ulcerative keratitis3.2%26
- Lacrimation increasedwatery eyes3.1%25
- Eye pruritus2.9%23
- Dyspnoeashortness of breath2.6%21
- Intraocular pressure increasedraised pressure in the eye2.6%21
- Dizzinesslight-headedness or unsteadiness2.5%20
- Cataractclouding of the eye lens2.4%19
- Hypopyon2.4%19
- Condition aggravatedthe condition being treated got worse2.2%18
- Conjunctival hyperaemia2.1%17
- Corneal epithelium defect2.1%17
- Corneal infiltrates2.1%17
- Erythemaskin redness2.1%17
- Photophobiasensitivity to light2.1%17
- Pruritusitching2.1%17
Top 30 of 261 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 7 drugs in the fluoroquinolone antibacterial class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 88,718 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 59.3% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Postoperative care | 85 | 10.6% |
| Cataract operation | 64 | 8% |
| Conjunctivitis | 32 | 4% |
| Intraocular lens implant | 26 | 3.2% |
| Preoperative care | 23 | 2.9% |
| Prophylaxis | 20 | 2.5% |
The indication field is filled in by the reporter and is often blank; shares are of all 801 reports.
In context
| Measure | Vigamox | Fluoroquinolone antibacterial | All reports |
|---|---|---|---|
| Reports as suspect product | 801 | 88,718 | 20,646,523 |
| Share of that pool | — | 0.9% | 0% |
| Reports, latest 12 months | 37 | — | 1,332,454 |
| Marked serious | 70.7% | 89.7% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 11 | 92 | 91 |
| Hospitalisation recorded, per 1,000 reports | 85 | 384 | 213 |
| Consumer-filed share | 32.8% | 23% | 45.8% |
| Top term, share of reports | Toxic anterior segment syndrome 11.7% | median 0% | 0% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the fluoroquinolone antibacterial class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Ciprofloxacin | generic | 39,570 | 2,405 | 88.2% |
| Levofloxacin | generic | 30,690 | 1,912 | 91.1% |
| Moxifloxacin | generic | 8,863 | 918 | 91.4% |
| Ciprofloxacin hydrochloride | generic | 3,653 | 375 | 94.2% |
| Moxifloxacin hydrochloride | generic | 3,116 | 542 | 96.7% |
| Ciprofloxacin hcl | generic | 2,025 | 0 | 81.7% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Vigamox reports
How many adverse event reports has FDA received for Vigamox?
801 reports list Vigamox as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 37 of them arrived in the latest 12 months. Another 1,573 list it only as a concomitant medication.
What reactions are recorded in Vigamox reports?
toxic anterior segment syndrome (11.7%), eye pain (10.5%), vision blurred (10.4%), ocular hyperaemia (9.1%) and off label use (9%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Vigamox was responsible.
How serious are the reports?
70.7% are marked serious by the reporter. Among the outcomes recorded, 1.1% of reports include death and 8.5% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (32.8%), other health professional (28.2%) and physician (25.7%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Vigamox rising?
37 reports in the 12 months to June 2026, up 106% from 18 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Vigamox was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Vigamox?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Vigamox as a suspect or interacting product; reports listing it only as a concomitant medication (1,573) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.